ReviewBreast cancer research and treatment2021
Immune microenvironment in different molecular subtypes of ductal breast carcinoma.
Review in Breast cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.Frontiers in endocrinology · 2023Pooled it
- DHX15 as a novel immune-related prognostic biomarker in breast cancer: An integrated bioinformatics analysis withOncology letters · 2026Article
- COG8 serves as a predictive and prognostic biomarker in lung adenocarcinoma and other human malignancies.Discover oncology · 2026Article
- Integrated pan-cancer analysis and experimental validation reveal that syndecan-1 drives glioblastoma pathogenesis and associates with immune infiltration.Discover oncology · 2026Article
- Circulating tumor cells as predictive biomarkers in the risk stratification of DCIS: Evidence of early dissemination.Science advances · 2025Article
- Development and validation of a gradient boosting machine-based model for predicting tumor-infiltrating lymphocyte proportions in breast cancer.American journal of translational research · 2025Article
- Circulating CD3Cancer medicine · 2025Article
- Cancer-associated fibroblasts in ovarian cancer: research progress.Frontiers in oncology · 2025Review
- Detecting cell types and densities in the tumor microenvironment improves prognostic risk assessment for breast cancer.Biomolecules & biomedicine · 2024Article
- The Genomic and Biologic Landscapes of Breast Cancer and Racial Differences.International journal of molecular sciences · 2024Review
- Single-cell transcriptome analysis reveals immune microenvironment changes and insights into the transition from DCIS to IDC with associated prognostic genes.Journal of translational medicine · 2024Article
- Non-genetic heterogeneity and immune subtyping in breast cancer: Implications for immunotherapy and targeted therapeutics.Translational oncology · 2024Article
- Expression and clinical significance of CLDN7 and its immune-related cells in breast cancer.Diagnostic pathology · 2024Article
- Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer.Molecular cancer · 2024Review
- Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.Signal transduction and targeted therapy · 2024Review
- Recent advances in understanding the immune microenvironment in ovarian cancer.Frontiers in immunology · 2024Review
- Advances in the study of tertiary lymphoid structures in the immunotherapy of breast cancer.Frontiers in oncology · 2024Review
- Machine learning-based cluster analysis of immune cell subtypes and breast cancer survival.Scientific reports · 2023Article
- Combining Cryo-Thermal Therapy with Anti-IL-6 Treatment Promoted the Maturation of MDSCs to Induce Long-Term Survival in a Mouse Model of Breast Cancer.International journal of molecular sciences · 2023Article
- Predicting breast cancer types on and beyond molecular level in a multi-modal fashion.NPJ breast cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeDuctal breast carcinoma as a heterogeneous disease has different molecular subtypes associated with clinical prognosis and patients' survival. The role of immune system as a consistent part of the tumor microenvironment (TME) has been documented in progression of ductal breast carcinoma. Here, we aimed to describe the important immune cells and the immune system-associated molecules in Ductal Carcinoma In situ (DCIS) and Invasive Ductal Carcinoma (IDC) with special emphasis on their associations with different molecular subtypes and patients' prognosis.
resultsThe immune cells have a dual role in breast cancer (BC) microenvironment depending on the molecular subtype or tumor grade. These cells with different frequencies are present in the TME of DCIS and IDC. The presence of regulatory cells including Tregs, MDSC, Th2, Th17, M2 macrophages, HLADR
conclusionDetermining the specific immune response in each subtype could be helpful in estimating the possible behavior of the tumor cells in TME. It is important to realize that different frequencies of immune cells in BC environment likely determine the patients' prognosis and their survival in each subtype. Therefore, elucidation of the distinct immune players in TME would be helpful toward developing targeted therapies in each subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.